Evidence map›Paper›PMID 36304454›Full record

ReviewFrontiers in immunology2022

Ferroptosis and musculoskeletal diseases: "Iron Maiden" cell death may be a promising therapeutic target.

Yili Zhang, Xinyi Huang, Baoyu Qi, Chuanrui Sun, Kai Sun, Ning Liu, Liguo Zhu, Xu Wei

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Identification of ferroptosis-related genes and potential drugs in osteoarthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yili ZhangSchool of Traditional Chinese Medicine and School of Integrated Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Xinyi HuangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Baoyu QiWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Chuanrui SunWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Kai SunWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Ning LiuWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liguo ZhuWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xu WeiWangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a novel form of cell death precisely regulated by iron metabolism, antioxidant processes, and lipid metabolism that plays an irreplaceable role in the development of many diseases. Musculoskeletal disorders (MSKs), including osteoporosis, osteoarthritis, rheumatoid arthritis, intervertebral disc degeneration, sarcopenia, and rhabdomyolysis, have become one of the most common causes of disability and a major burden on public health and social care systems. The mechanism of ferroptosis in MSKs has recently been elucidated. In this review, we briefly introduce the ferroptosis mechanism and illustrate the pathological roles of ferroptosis in MSKs with a focus on how ferroptosis can be exploited as a promising treatment strategy. Notably, because the toxicity of compounds that inhibit or induce ferroptosis in other organs is largely unknown, ferroptosis appears to be a double-edged sword. We point out that more research is needed in the future to verify the therapeutic effects based on ferroptosis in MSKs.

Indexed as

FerroptosisRhabdomyolysisAntioxidantsCell DeathHumansIronAntioxidantsIronimmunologyinflammationmechanismoxidative stressregulated cell death

Identifiers

PMID36304454
PMCPMC9595130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.